Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABO blood type incompatibility lost the unfavorable impact on outcome in unrelated bone marrow transplantation.
Kimura F, Kanda J, Ishiyama K, Yabe T, Yoshifuji K, Fukuda T, Ozawa Y, Iwato K, Eto T, Mori T, Uchida N, Ota S, Sakura T, Ichinohe T, Atsuta Y, Kanda Y; donor/source working group of the Japan Society for Hematopoietic Cell Transplantation. Kimura F, et al. Among authors: yoshifuji k. Bone Marrow Transplant. 2019 Oct;54(10):1676-1685. doi: 10.1038/s41409-019-0496-2. Epub 2019 Mar 13. Bone Marrow Transplant. 2019. PMID: 30867557
Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation.
Kaito S, Sekiya N, Najima Y, Suzuki T, Wada A, Adachi H, Konuma R, Kishida Y, Nagata A, Konishi T, Yamada Y, Kumagai T, Inamoto K, Yoshifuji K, Akiyama M, Toya T, Igarashi A, Muto H, Doki N, Kobayashi T, Kakihana K, Ohashi K. Kaito S, et al. Among authors: yoshifuji k. Bone Marrow Transplant. 2020 Mar;55(3):661-664. doi: 10.1038/s41409-019-0541-1. Epub 2019 May 29. Bone Marrow Transplant. 2020. PMID: 31142797 No abstract available.
Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
Najima Y, Sadato D, Harada Y, Oboki K, Hirama C, Toya T, Doki N, Haraguchi K, Yoshifuji K, Akiyama M, Inamoto K, Igarashi A, Kobayashi T, Kakihana K, Okuyama Y, Sakamaki H, Harada H, Ohashi K. Najima Y, et al. Among authors: yoshifuji k. Bone Marrow Transplant. 2021 Feb;56(2):334-346. doi: 10.1038/s41409-020-01016-9. Epub 2020 Aug 5. Bone Marrow Transplant. 2021. PMID: 32760007
[Vacuolar myelopathy after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia].
Kumagai T, Doki N, Kobayashi T, Yamada R, Hishima T, Adachi H, Konuma R, Fujita M, Wada A, Kishida Y, Konishi T, Nagata A, Yamada Y, Kaito S, Yoshifuji K, Mukae J, Akiyama M, Inamoto K, Toya T, Igarashi A, Najima Y, Kakihana K, Sakamaki H, Ohashi K. Kumagai T, et al. Among authors: yoshifuji k. Rinsho Ketsueki. 2020;61(11):1625-1627. doi: 10.11406/rinketsu.61.1625. Rinsho Ketsueki. 2020. PMID: 33298658 Japanese.
Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease.
Konishi T, Kusakabe S, Hino A, Inamoto K, Yoshifuji K, Kiridoshi Y, Takeshita K, Sasajima S, Toya T, Igarashi A, Najima Y, Kobayashi T, Doki N, Motooka D, Nakamura S, Suyama M, Suda W, Shiota A, Atarashi K, Hattori M, Honda K, Yokota T, Ohashi K, Shibayama H, Fukushima K, Kakihana K. Konishi T, et al. Among authors: yoshifuji k. Bone Marrow Transplant. 2021 Jul;56(7):1728-1731. doi: 10.1038/s41409-021-01249-2. Epub 2021 Mar 8. Bone Marrow Transplant. 2021. PMID: 33686248 No abstract available.
Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S, Najima Y, Sadato D, Hirama C, Kishida Y, Nagata A, Konishi T, Yamada Y, Kurosawa S, Yoshifuji K, Shirane S, Shingai N, Toya T, Shimizu H, Haraguchi K, Kobayashi T, Harada H, Okuyama Y, Harada Y, Doki N. Kaito S, et al. Among authors: yoshifuji k. Bone Marrow Transplant. 2024 Aug;59(8):1169-1175. doi: 10.1038/s41409-024-02311-5. Epub 2024 May 23. Bone Marrow Transplant. 2024. PMID: 38783125
Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
Kurosawa S, Toya T, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, Yoshifuji K, Matsuyama N, Shirane S, Uchida T, Inamoto K, Igarashi A, Najima Y, Muto H, Kobayashi T, Doki N, Kakihana K, Sakamaki H, Ohashi K. Kurosawa S, et al. Among authors: yoshifuji k. Leuk Lymphoma. 2018 Dec;59(12):3006-3009. doi: 10.1080/10428194.2018.1441410. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616841 No abstract available.
Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation.
Kurosawa S, Doki N, Senoo Y, Kishida Y, Nagata A, Yamada Y, Konishi T, Kaito S, Yoshifuji K, Matsuyama N, Shirane S, Uchida T, Inamoto K, Toya T, Igarashi A, Najima Y, Muto H, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K. Kurosawa S, et al. Among authors: yoshifuji k. Ann Hematol. 2020 Aug;99(8):1873-1882. doi: 10.1007/s00277-020-04090-7. Epub 2020 May 25. Ann Hematol. 2020. PMID: 32451708 Clinical Trial.
65 results